While human infections of the highly pathogenic H5N1 “bird flu” virus remain low, patients may still have questions.

Loren Bonner

Federal agencies have been working toward potentially changing the drug schedule of cannabis for several years. However, a recent decision by a DEA judge has caused a delay in moving this process forward.

Olivia C. Welter, PharmD

In January 2025, FDA approved Journavx (suzetrigine), a first-in-class non-opioid analgesic, for the treatment of moderate to severe acute pain.

Lauren Howell, PharmD

Mary Warner

Over half of all Americans take a daily multi-vitamin or dietary supplement with recent polls showing that number may be rising. Meanwhile, the incidence of documented cases of supplement-induced liver damage has also been rising.

Mickie Cathers